Brind.

European ADRs Soften Amid Declines in Cellectis and Nokia Trading

1 report, 1 independent Updated 14:45
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

On November 19, 2026, Cellectis shed 8.43% during late morning trading, making it the hardest-hit European name in the U.S. market. Nokia was the second-largest decliner in the group, falling 3.86%. DBV Technologies and Foce registered no movement on the day, while the losses contributed to a broader softening across European ADRs.

From foreignpolicyjournal.com

Why it matters

Some supportBrind's analysis of the reports

The trading activity illustrates an uneven environment for European names seeking U.S. capital. The broad weakness across multiple European ADRs suggests that risk appetite for non-U.S. equities remained under pressure.

From foreignpolicyjournal.com

Who's involved

  • NokiaFinnish telecommunications company that declined 3.86% during the trading session.
  • CellectisBiopharmaceutical company that experienced a sharp drop of 8.43%.
  • DBV TechnologiesFrench biopharmaceutical firm that remained flat during the trading session.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • NokiaSpeculative

    Nokia might face pressure on revenue due to the broader sell-off in European ADRs.

  • CellectisSpeculative

    Cellectis could see reduced investment funding due to the broader sell-off in European ADRs.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped